Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Insurance Subsidy Impact on New TKI Users Assessed

Cancer; ePub 2017 Oct 4; Shen, Zhao, Liu, et al

New users of tyrosine kinase inhibitors (TKIs) who had heavily subsidized insurance with significantly lower out-of-pocket costs were more apt to be nonadherent, according to a study involving 836 individuals. Participants with Medicare Part D coverage had chronic myeloid leukemia and were prescribed TKIs for the first time. Investigators looked at the relationship between out-of-pocket costs per 30-day drug supply, Medicare Part D plan characteristics, and treatment adherence. Among the results:

  • 3 of every 10 patients were nonadherent during the first 6 months of treatment.
  • Patients with heavily subsidized coverage were nearly 7 times more likely to be nonadherent vs those without a subsidy.
  • Patients who were moderately subsidized were 3 times more likely to be nonadherent.


Shen C, Zhao B, Liu L, Shih Y. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. [Published online ahead of print October 4, 2017]. Cancer. doi:10.1002/cncr.31050.